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Dengue is a arboviral infection that represents a major global health burden. There is an unmet need for effective
dengue therapeutics to reduce symptoms, duration of illness and incidence of severe complications. Here, we con-
sider the merits of a dengue human infection model (DHIM) for drug development. A DHIM could allow exper-
imentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using
smaller sample sizes than trials that recruited patients with dengue in an endemic country. In addition, the
DHIM would assist the conduct of intensive pharmacokinetic and basic research investigations and aid in deter-
mining optimal drug dosage. Furthermore, a DHIM could help establish proof of concept that chemoprophylaxis
against dengue is feasible. The key challenge in developing the DHIM for drug development is to ensure the model
reliably replicates the typical clinical and laboratory features of naturally acquired, symptomatic dengue.
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The 4 serotypes of dengue virus (DENV-1 to DENV-4)
are the most important arboviral pathogens of humans.
The global burden of dengue, recently estimated at ap-
proximately 100 million cases per year, remains unchal-
lenged by licensed vaccines or sustainable vector control
strategies [1]. The scale of the dengue burden in the en-
demic countries of Asia and Latin America has a nega-
tive economic impact and places a signiﬁcant clinical
burden on often fragile health care systems [2–4].
Dengue is an acute systemic febrile illness that man-
ifests with abrupt onset as an undifferentiated fever that
is difﬁcult to distinguish from other infections without
laboratory diagnostic tests [1]. Headache, malaise, my-
algia, retro-orbital pain are common symptoms in
adults [5]. The clinical features differ by age group,
with symptoms such as cough, vomiting and abdominal
pain more common in children [6]. Leukopenia and
thrombocytopenia are common laboratory features.
In most cases, fever and symptoms resolve unevent-
fully after 3–7 days with no long-term sequelae [1]. In a
subset of cases, a transient vascular leakage syndrome
develops after 3–4 days of illness, which, when severe,
can lead to life-threatening hypovolemic shock (called
dengue shock syndrome) and/or hemorrhage [1, 5].
The vascular leak syndrome may be associated with
complement activation and a coagulopathy that can
contribute to the risk of hemorrhage [7, 8]. Signs of vas-
cular leakage include an increasing hematocrit, micro-
albuminuria, or the accumulation of ﬂuids at serosal
surfaces (eg, pleural effusions) [5].
Supportive care and the careful titration of mini-
mum volumes of parenteral crystalloid ﬂuids to main-
tain stable cardiac output during the 1–3-day period
of vascular permeability are critical elements in dengue
case management [5].Vasopressors are commonly used
in cases with prolonged shock. Clinically signiﬁcant
hemorrhage requiring use of blood products is more
common in adults than in children [9].
Improvements in the management of severe dengue
cases have seen the case mortality rate decline over the
last decade in many but not all endemic settings [10–
12]. At present there is no validated way of identifying
which patients will progress to more severe disease, mean-
ing that health facilities in endemic areas are often
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overwhelmed with patients with dengue who require ongoing ob-
servation as outpatients or are admitted for inpatient observation.
THE CASES FOR DENGUE THERAPEUTIC AND
PROPHYLACTIC AGENTS
Antivirals
A drug that can shorten the duration of illness and reduce the
risk of disease progression would be a signiﬁcant advance for
both patients and for overstretched health systems in dengue-
endemic countries. An obvious approach is to target virus rep-
lication with a small molecule antiviral drug that given early in
the course of illness has the potential to shorten the duration of
infection. Moreover, because high early DENV viremia levels
are a risk factor for the development of more severe disease,
an antiviral drug might also reduce the incidence of severe com-
plications [13, 14]. In addition, a drug that reduces the magni-
tude and duration of viremia has the potential to reduce onward
DENV transmission by reducing the length of time an individ-
ual patient is infectious to mosquitoes [15]. Alternatives to
small molecule antiviral drugs include therapeutic monoclonal
antibodies; however, high costs and requirement for parenteral
administration are currently barriers to their use.
Disease Modulators
Both host and virus factors are important in inﬂuencing the
outcome of DENV infection. A range of host factors, such as
age, sex, genotype, and ﬂavivirus infection history, inﬂuence
the disease outcome [10, 16, 17]. Because the manifestations
of severe dengue are typically observed in secondary DENV in-
fections and when innate and adaptive immune responses have
driven steep declines in viremia levels, it is widely held that the
immune system plays an important role in disease pathogenesis
[18]. This represents the rationale for use of an immunomodu-
latory drug that can favorably modulate the poorly deﬁned im-
munopathogenic mechanisms postulated to underlie severe
dengue. It is possible that the dichotomous approach of target-
ing either the virus or the immune response is an oversimpliﬁed
strategy to the development of dengue therapeutics. Other phys-
iological systems are involved in the control of endothelial in-
tegrity, but their role in dengue remains poorly understood [19].
Prophylaxis
Avaccine would be the most effective prophylactic public health
intervention for control of dengue, but the development of an
efﬁcacious tetravalent dengue vaccine is proving to be a chal-
lenge [20, 21]. An alternative or adjunctive approach is the
use of drug chemoprophylaxis in the community. Chemopro-
phylaxis using oseltamivir has been advocated for controlling
the spread of inﬂuenza within households and was commonly
used in some settings during the 2009 H1N1 inﬂuenza pandem-
ic, creating a precedent for such an approach for an acute viral
infection [22, 23]. The safety proﬁle of a prophylactic dengue
drug would have to be exemplary, and there are major questions
of whether this approach could be cost-effective and sustain-
able, given the temporally and spatially heterogenous patterns
of DENV transmission in endemic regions [24, 25]. Moreover,
in most dengue-endemic regions a signiﬁcant fraction of the
population is already immune and will not beneﬁt from chemo-
prophylaxis. Consequently, in endemic areas the number need-
ed to treat, and the duration they need to be treated for, may be
large for the prevention of a single symptomatic case and very
large for the prevention of severe cases. There is a marginally
stronger argument for chemoprophylaxis in populations with
no immunity to DENV. Examples of this include dengue-
naive travelers or military personnel who are transiently present
in areas of high DENV transmission. Similarly, chemopro-
phylaxis could be indicated for communities experiencing “vir-
gin soil” dengue outbreaks because of importation by viremic
travelers or infected mosquitoes.
PREVIOUS CLINICAL TRIALS OF
THERAPEUTICS FOR DENGUE AND
RELEVANCE TO THE DENGUE HUMAN
INFECTION MODEL
For a disease with an estimated global burden prevalence of 100
million cases per year, remarkably few clinical trials of treat-
ment approaches have been performed. Early trials tested
ﬂuid resuscitation approaches in patients with hypovolemic
shock [26–28]. More-recent trials have tested the candidate
antiviral agents chloroquine and balapiravir or have targeted
the immune response by use of oral corticosteroids [29–31]. Al-
though none of these trials have demonstrated therapeutic efﬁ-
cacy, they have provided a framework for the conduct of such
trials and has led to the publication of recommendations for a
standardized approach to dengue clinical trial design and con-
duct [15]. In addition, a trial of lovastatin in dengue is currently
underway and further trials are planned [15, 32]. The virological
ﬁndings in these trials, consistent with previous literature, have
underscored the need for antiviral therapy to commence early
in the course of illness, because illness resolves and patients are
no longer infectious to Aedes aegypti mosquitoes by 5–7 days
after illness onset [14, 15, 33–35].
POTENTIAL ROLES FOR A HUMAN INFECTION
MODEL IN DENGUE DRUG DEVELOPMENT
In principal, a dengue human infection model (DHIM) pro-
vides opportunities for fast-tracking dengue drug development,
particularly therapeutic and prophylactic antivirals. The overall
strength of the DHIM is that it allows for controlled prophy-
lactic or therapeutic studies of DENV infection in susceptible
participants who have been preselected for a set of desirable
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characteristics. In contrast, prophylactic or therapeutic studies
of DENV infection in an endemic country population are sub-
ject to the vagaries of ethnic diversity of the patient population,
ﬂuctuating serotype and genotype prevalence, variable viremia
levels, and prior ﬂavivirus infection histories. Collectively, these
sources of variation in an endemic country population probably
boost the required patient sample size required for detection of
therapeutic or clinical safety signals.
CRITICAL HURDLES FOR A DHIM
Central to the usefulness of a DHIM is whether it mimics the
main features of a symptomatic dengue case. This is a funda-
mental and critical hurdle in the development of a successful
DHIM for use in dengue therapeutic development. Thus, the
kinetics of clinical, virological, hematological, and biochemical
changes that are typically present in a naturally acquired and
clinically uncomplicated adult dengue case should also manifest
in the adult DHIM. In the beginning, at least, we assume that
the DHIM will involve participants who are ﬂavivirus naive,
and thus all experimental infections will be primary infections.
In the context of dengue drug development, the characteristics
of a symptomatic, naturally acquired DENV infection that a
DHIM would need to replicate include acquisition of infection
and certain clinical, virological, and laboratory features.
Acquisition of Infection
ADHIM could use DENV-infected mosquitoes to elicit infection
in human volunteers. Although this approach may be optimal in
replicating the natural history of DENV infection because, for
Table 1. Early-Phase Clinical Studies of Antiviral Drugs: Strengths and Weaknesses of the DHIM vs Trial Conducted in a Dengue-
Endemic Setting
Hurdle DHIM
Dengue-Endemic
Setting Notes
Dengue case burden At call Usually seasonal and
with yearly variation
in case numbers
In endemic settings dependent on the force of
infection
Clinical research capacity Available Variable In endemic settings dependent on local
expertise, experience and resources
Efficiency of regulatory system Variable Variable In endemic settings dependent on research
infrastructure and local regulatory
requirements
Accredited testing laboratories Available Variable In endemic settings dependent on research
infrastructure and local regulatory
requirements
Ability to ship research specimens
across international borders
Yes Variable In endemic settings dependent on research
infrastructure and local regulatory
requirements
Variance in viremia and serotypes Serotype controlled;
possibly less
variance in viremia
Variable In endemic settings dependent on local viral
epidemiology
Early therapy possible Yes Variable In endemic settings dependent on patients
presenting early
Pharmacokinetic studies Yes Yes/Variable May require international shipping of samples
from endemic countries
Intensive pathophysiological monitoring Yes Possibly Ability to conduct intensive monitoring is
dependent on the local resources available
Chemoprophylaxis studies Yes More difficult The controlled setting of the DHIM is ideally
suited to this kind of study
Provide proof of concept that therapy
reduces major clinical complications
Probably not, requires
large sample sizes
Yes Severe clinical events in healthy adults with
primary DENV infections are rare
Provide proof of concept that therapy
mitigates typical lab features
Probably not, requires
large sample sizes
Yes Demonstrating mitigation would require large
sample size
Serious adverse events; clinical
experience of managing severe
dengue
Variable Yes Extensive clinical experience and expertise in
endemic settings
Clinical studies of secondary heterotypic
DENV infections
Difficult Yes Ethical hurdles for the DHIM in view of known
risks associated with secondary heterotypic
infections
Clinical studies in participants who have
received dengue vaccine candidates
Yes Yes In the DHIM will depend on the balance of
perceived risks and benefits
Abbreviations: DENV, dengue virus; DHIM, dengue human infection model.
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example, the immunoregulatory effects of mosquito saliva would
be replicated, it may present additional regulatory and logistical
hurdles. Alternatively, a DHIM could use subcutaneous inocula-
tion of laboratory-cultured virus, as used in the challenge exper-
iments by Sun and colleagues [36]. This approach bypasses
issues surrounding use of mosquitoes, although it remains to
be determined if there are material differences between needle-
delivered and mosquito-delivered DENV infection.
Clinical Features
Typical signs and symptoms of dengue that a DHIM would need
to replicate in otherwise healthy adults include fever, headache,
myalgia, musculoskeletal pain, and nausea or vomiting [37].
Minor hemorrhagic features may occur between days 3 and 6
of illness (eg, petechiae) [37]. Prevention or rapid amelioration
of these self-limiting symptoms will be a target of dengue thera-
peutic drug development. Primary infections in otherwise healthy
adults are rarely associated with severe clinical complications, but
it would be prudent to exclude the elderly and those with comor-
bid conditions from the volunteer pool, because these groups are
at elevated risk of severe complications [38, 39].
Virological Features
The intrinsic incubation period of DENV infection has been es-
timated to be between 4–10 days [5].Work that reanalyzed his-
torical mosquito exposure experiments estimated that the
intrinsic incubation period in primary infection was approxi-
mately 6 days [40]. The duration of viremia varies by serotype
and DENV infection history. The peak viremia level is often not
observed in naturally occurring infections because it precedes
the time point when patients attend health care facilities, but
ﬁndings suggest that the peak level occurs later in primary in-
fections as compared to secondary [33]. Studies suggest that pri-
mary infections with DENV-1 are associated with a longer
viremic period and higher viremia levels [33, 41]. An optimal
DHIM would replicate the virological features of a naturally
acquired DENV infection to enable conﬁdent predictions of
therapeutic or prophylactic drug efﬁcacy in the ﬁeld.
Laboratory Features
A DHIM should elicit thrombocytopenia and leukopenia, both
typical features in patients with primary or secondary dengue.
In addition, many patients have minor elevations in transami-
nase and creatine kinase levels [9, 42]. Clotting abnormalities
are also often observed in severe cases with elevated activated
partial thromboplastin times and reduced levels of ﬁbrinogen;
however, these occur less frequently in primary infections [43].
STRENGTHS AND WEAKNESSES OF A DHIM
FOR DRUG DEVELOPMENT
The strengths and weaknesses of a DHIM for performing
early-phase clinical studies compared to performing such
studies in naturally acquired cases in an endemic country are
summarized in Table 1. In short, the great advantage of the
DHIM for early-phase drug development is the ability to per-
form controlled prophylactic or early therapeutic studies in a
setting amenable to intensive pharmacological and basic re-
search investigations.
FOCUS AREAS IN WHICH THE DHIM COULD
SUBSTANTIALLY ADVANCE CLINICAL DRUG
DEVELOPMENT
ADHIM that mimics natural infection would be particularly well
suited to early-phase studies of chemoprophylaxis and accompa-
nying pharmacokinetic studies, in which the timing of treatment
and infection can be controlled. In contrast, in a dengue-endemic
country, early-phase chemoprophylaxis trials would require large
and lengthy community-based cohort studies, as has been used
to derive evidence for oseltamivir in the chemoprophylaxis of in-
ﬂuenza [22]. The DHIM would thus be a more cost-effective and
time-efﬁcient route to acquiring proof of concept evidence that
chemoprophylaxis for dengue is possible. For a given antiviral
drug, a DHIMwould also be well-suited for studies that accurate-
ly deﬁne the therapeutic window in symptomatic cases, since the
time of infection, onset of symptoms and treatment will be pro-
spectively documented. In contrast, in endemic countries enroll-
ment of study participants is dependent on patients seeking
health care, who will have various durations of illness history at
the time of study enrollment. A DHIM can also aid the develop-
ment of alternative therapeutic approaches, such as immuno-
modulatory agents. In addition, a DHIM may aid the
development of noninvasive physiological monitoring tech-
niques within clinical trials, perhaps through the identiﬁcation
of appropriate physiological measurements that could be used
as end points [15].
In conclusion, the work of Sun and colleagues [36] has shown
that a DHIM is possible. This is a signiﬁcant advance in the ﬁeld
with the potential to contribute to the development of successful
dengue therapeutics and much else. The future use of the DHIM
in dengue clinical research will require a signiﬁcant investment
from multiple stakeholders. Its contribution in drug development
may aid in the selection of appropriate candidate drugs for further
development and assist pharmacokinetic studies. The potential
signiﬁcance of these contributions suggests that investing in a
DHIM is both appropriate and timely.
Notes
Financial support. This work was supported by fellowships from the
Wellcome Trust of the United Kingdom (grants 097430/Z/11/Z to J.W.
and 084368/Z/07/Z to C.P.S.).
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
Dengue Human Challenge for Drug Development • JID 2014:209 (Suppl 2) • S69
References
1. Simmons CP, Farrar JJ, Nguyen VV, Wills B. Dengue. N Engl J Med
2012; 366:1423–32.
2. ShepardD,Coudeville L,HalasaY,ZambranoB,DayanG.Economic impact
of dengue illness in the Americas. Am J Trop Med Hyg 2011; 84:200–7.
3. Shepard DS, Undurraga EA, Lees RS, Halasa Y, Lum LC, Ng CW. Use of
multiple data sources to estimate the economic cost of dengue illness in
Malaysia. Am J Trop Med Hyg 2012; 87:796–805.
4. Wettstein ZS, Fleming M, Chang AY, et al. Total economic cost and
burden of dengue in Nicaragua: 1996–2010. Am J Trop Med Hyg
2012; 87:616–22.
5. WHO. Dengue: guidelines for diagnosis, treatment, prevention and con-
trol: new edition. Geneva, Switzerland: World Health Organization, 2009.
6. Hanafusa S, Chanyasanha C, Sujirarat D, Khuankhunsathid I, Yaguchi
ASuzuki T. Clinical features and differences between child and adult
dengue infections in Rayong Province, Southeast Thailand. Southeast
Asian J Trop Med Public Health 2008; 39:252–9.
7. Bokisch VA, Top FH Jr, Russell PK, Dixon FJ, Muller-Eberhard HJ. The
potential pathogenic role of complement in dengue hemorrhagic shock
syndrome. N Engl J Med 1973; 289:996–1000.
8. Wills B, Tran VN, Nguyen TH, et al. Hemostatic changes in Vietnamese
children with mild dengue correlate with the severity of vascular leakage
rather than bleeding. Am J Trop Med Hyg 2009; 81:638–44.
9. Trung DT, Thao le TT, Dung NM, et al. Clinical features of dengue in a
large Vietnamese cohort: intrinsically lower platelet counts and greater risk
for bleeding in adults than children. PLoS Negl Trop Dis 2012; 6:e1679.
10. Anders KL, Nguyet NM, Chau NV, et al. Epidemiological factors asso-
ciated with dengue shock syndrome and mortality in hospitalized
dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg
2011; 84:127–34.
11. Lumbiganon P, Kosalaraksa P, Thepsuthammarat K, Sutra S. Dengue
mortality in patients under 18 years old: an analysis from the health sit-
uation analysis of Thai population in 2010 project. J Med Assoc Thai
2012; 95(Suppl 7):S108–13.
12. Moraes GH, de Fatima Duarte E, Duarte EC. Determinants of mortality
from severe dengue in Brazil: a population-based case-control study.
Am J Trop Med Hyg 2013; 88:670–6.
13. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the
dengue virus nonstructural protein NS1 early in dengue illness correlate
with the development of dengue hemorrhagic fever. J Infect Dis 2002;
186:1165–8.
14. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, an-
tibody response pattern, and virus serotype correlate with disease se-
verity. J Infect Dis 2000; 181:2–9.
15. Simmons CP, Wolbers M, Nguyen MN, et al. Therapeutics for dengue:
recommendations for design and conduct of early-phase clinical trials.
PLoS Negl Trop Dis 2012; 6:e1752.
16. Kouri GP, Guzman MG, Bravo JR, Triana C. Dengue haemorrhagic
fever/dengue shock syndrome: lessons from the Cuban epidemic,
1981. Bull World Health Organ 1989; 67:375–80.
17. Khor CC, Chau TN, Pang J, et al. Genome-wide association study iden-
tiﬁes susceptibility loci for dengue shock syndrome at MICB and
PLCE1. Nat Genet 2011; 43:1139–41.
18. Green S, Rothman A. Immunopathological mechanisms in dengue and
dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429–36.
19. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular
integrity by endothelial cell junctions: molecular basis and pathological
implications. Dev Cell 2009; 16:209–21.
20. Halstead SB. Dengue vaccine development: a 75% solution? Lancet
2012; 380:1535–6.
21. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efﬁcacy of
the recombinant, live-attenuated, CYD tetravalent dengue vaccine in
Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet
2012; 380:1559–67.
22. Hayden FG, Belshe R, Villanueva C, et al. Management of inﬂuenza in
households: a prospective, randomized comparison of oseltamivir
treatment with or without postexposure prophylaxis. J Infect Dis
2004; 189:440–9.
23. Lee VJ, Yap J, Cook AR, et al. Oseltamivir ring prophylaxis for contain-
ment of 2009 H1N1 inﬂuenza outbreaks. N Engl J Med 2010;
362:2166–74.
24. Cummings DA, Irizarry RA, Huang NE, et al. Travelling waves in the
occurrence of dengue haemorrhagic fever in Thailand. Nature 2004;
427:344–7.
25. Balmaseda A, Standish K, Mercado JC, et al. Trends in patterns of
dengue transmission over 4 years in a pediatric cohort study in Nicara-
gua. J Infect Dis 2010; 201:5–14.
26. Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock
syndrome: a randomized double-blind comparison of 4 intravenous
ﬂuid regimens in the ﬁrst hour. Clin Infect Dis 2001; 32:204–13.
27. Dung NM, Day NP, Tam DT, et al. Fluid replacement in dengue shock
syndrome: a randomized, double-blind comparison of four intrave-
nous-ﬂuid regimens. Clin Infect Dis 1999; 29:787–94.
28. Wills BA, NguyenMD, Ha TL, et al. Comparison of three ﬂuid solutions
for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:
877–89.
29. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of
chloroquine for the treatment of dengue in Vietnamese adults. PLoS
Negl Trop Dis 2010; 4:e785.
30. Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corti-
costeroid therapy in early dengue infection in Vietnamese patients: a
randomized, placebo-controlled trial. Clin Infect Dis 2012; 55:
1216–24.
31. Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind
placebo controlled trial of balapiravir, a polymerase inhibitor, in adult
dengue patients. J Infect Dis 2013; 207:1442–50.
32. Whitehorn J, Van Vinh Chau N, Truong NT, et al. Lovastatin for adult
patients with dengue: protocol for a randomised controlled trial. Trials
2012; 13:203.
33. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of vire-
mia and NS1 antigenemia are shaped by immune status and virus sero-
type in adults with dengue. PLoS Negl Trop Dis 2011; 5:e1309.
34. Libraty DH, Endy TP, Houng HS, et al. Differing inﬂuences of virus
burden and immune activation on disease severity in secondary
dengue-3 virus infections. J Infect Dis 2002; 185:1213–21.
35. Nguyet MN, Duong TH, Trung VT, et al. Host and viral features of
human dengue cases shape the population of infected and infectious
Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 2013;
110:9072–7.
36. Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus chal-
lenge of human subjects previously vaccinated with live attenuated tet-
ravalent dengue vaccines. J Infect Dis 2013; 207:700–8.
37. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and
laboratory indicators of acute dengue illness. J Infect Dis 1997;
176:313–21.
38. Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection
in travelers: risk factors and laboratory indicators. J Infect Dis 2007;
195:1089–96.
39. Itoda I, Masuda G, Suganuma A, et al. Clinical features of 62 imported
cases of dengue fever in Japan. Am J Trop Med Hyg 2006; 75:470–4.
40. Nishiura H, Halstead SB. Natural history of dengue virus (DENV)-1
and DENV-4 infections: reanalysis of classic studies. J Infect Dis
2007; 195:1007–13.
41. Duyen HT, Ngoc TV, Ha do T, et al. Kinetics of plasma viremia and
soluble nonstructural protein 1 concentrations in dengue: differential
effects according to serotype and immune status. J Infect Dis 2011;
203:1292–300.
42. Trung DT, Thao le TT, Hien TT, et al. Liver involvement associated with
dengue infection in adults in Vietnam. Am J Trop Med Hyg 2010;
83:774–80.
43. Wills BA, Oragui EE, Stephens AC, et al. Coagulation abnormalities in
dengue hemorrhagic fever: serial investigations in 167 Vietnamese
children with dengue shock syndrome. Clin Infect Dis 2002; 35:277–85.
S70 • JID 2014:209 (Suppl 2) • Whitehorn et al
